Yarrow Biotechnology, Inc.

The failure of ProQR Therapeutics N.V. ’s sepofarsen in CEP290-mediated Leber congenital amaurosis 10 (LCA10), an inherited retinal disease (IRD), in a pivotal Phase II/III study was a surprise, but

In its second deal around an RNA-based approach to drug development this year, Eli Lilly and Company agreed on 8 September to partner with ProQR Therapeutics N.V. on an effort to develop five nove

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’